Intellectual Property Trends for Life Sciences Companies In a COVID (and post-COVID) World
Date:
Time:
The life sciences industry has been quite busy over the past year—and that’s an understatement. Intellectual property lawyers, in particular, have been working overtime to meet the needs of their organizations and bring solutions to market.
In this one-hour webinar, Carol Warren Simon and Amy Katz, sat down with the IP leadership from Genentech, Alexion, Sangamo Therapeutics, Inc. and Danaher to discuss how COVID-19 has impacted their organization’s IP activities and efforts. Together, they explored:
- COVID’s impact on the process of obtaining patents, as well as on patent litigation.
- How working remotely has impacted the daily life of IP attorneys and their ability to stay close to scientists.
- What are the biggest IP challenges in the coming year.
- How COVID and the economic fallout of COVID changed the way companies view IP or hire for it.
Panelists:
- Mony Ghose, VP and Chief Counsel IP, Danaher Corporation
- Laurie Hill, VP, Intellectual Property, Genentech
- Wendy Petka, VP, Intellectual Property, Sangamo Therapeutics, Inc.
- Todd Spalding, SVP and Head of Intellectual Property, Alexion Pharmaceuticals
Hosts:
Carol Warren Simon
Managing Director at Major, Lindsey & Africa
Amy Katz
Managing Director at Major, Lindsey & Africa